Table 1.
Patient characteristics for all patients and for patients diagnosed with VTE and those with no VTE during the ICU stay
| Variable | Total (n = 56) | No VTE (n = 48) | VTE (DVT ± PE; n = 3, PE n = 5) |
|---|---|---|---|
| Age, years (SD) | 62.3 (13.5) | 61.6 (14.4) | 65.5 (3.6) |
| Female sex n(%) | 13 (23) | 13 (27) | 0 (0) |
| BMI, kg/m2 (IQR) | 29.0 (26.7–34.0) | 29.2 (26.6–34.1) | 28.5 (27.2–31.6) |
| Hypertension n(%) | 29 (52) | 23 (48) | 6 (75) |
| Pulmonary disease | |||
| Asthma n(%) | 10 (18) | 9 (19) | 1 (13) |
| COPD n(%) | 5 (8.9) | 5 (10) | 0 (0) |
| Unspecified n(%) | 1 (1.8) | 1 (2.1) | 0 (0) |
| Ischemic heart disease n(%) | 7 (13) | 6 (13) | 1 (13) |
| History of VTE n(%) | 2 (3.6) | 1 (2.1) | 1 (13) |
| Diabetes mellitus n(%) | 12 (21) | 10 (21) | 2 (25) |
| Ongoing smoking n(%) | 4 (7.3) | 4 (8.5) | 0 (0) |
| Previous smoking n(%) | 12 (22) | 10 (21) | 2 (25) |
| Heart failure n(%) | 2 (3.6) | 2 (4.2) | 0 (0) |
| Days from symptom onset at ICU admission, (IQR) | 10 (8–12) | 9 (8–11) | 10 (9–13) |
| SAPS 3 score at ICU admission (SD) | 53 (10) | 53 (10) | 52 (8) |
| Parenteral anticoagulation prior to DVT screening | |||
| Prophylactic dose n(%) | 46 (82) | 43 (90) | 3 (38) |
| Therapeutic dose n(%) | 5 (8.9) | 0 (0) | 5 (63) |
Data are presented as mean (standard deviation), median (interquartile range) and absolute numbers (percentages). VTE Venous thromboembolism, BMI Body mass index, COPD Chronic obstructive pulmonary disease, PE Pulmonary embolism, DVT Deep vein thrombosis, ICU Intensive care unit, SAPS 3: Simplified Acute Physiology Score 3 [32]